What drugs are recommended for the treatment of gynecomastia?

Pharmacological Treatment of Gynecomastia

For drug-induced gynecomastia, discontinue the offending agent; for idiopathic or persistent cases, tamoxifen 20 mg daily for 3-6 months is the most effective pharmacological treatment, particularly for recent-onset glandular ("lump") gynecomastia. 1, 2

Prevention of Drug-Induced Gynecomastia

Prophylactic breast irradiation (8-15 Gy in 1-3 fractions) should be administered 1-2 weeks before initiating antiandrogen therapy in prostate cancer patients to prevent painful gynecomastia. 3, 4 This is particularly important for patients receiving long-term bicalutamide monotherapy, where breast bud irradiation (8-10 Gy in one fraction) prevents this complication. 3

First-Line Pharmacological Treatment

Tamoxifen (Selective Estrogen Receptor Modulator)

Tamoxifen 20 mg once daily for 6-12 weeks is the drug of choice for physiological gynecomastia. 2

• Efficacy: Achieves complete or partial resolution in 83% of cases overall, with 100% success rate in retro-areolar "lump" type gynecomastia versus 62.5% in diffuse "fatty" type. 2
• Symptom relief: Resolves tenderness in 84% of cases. 2
• Duration: Treatment for 3-6 months is typically required. 1
• Best candidates: Most effective in recent-onset glandular gynecomastia rather than long-standing cases with significant fibrosis. 1, 2

Alternative Pharmacological Options

Aromatase Inhibitors

Aromatase inhibitors (anastrozole) can be used for testosterone-induced gynecomastia but are generally not recommended as first-line therapy. 5, 6

• Anastrozole has been successfully used in men developing gynecomastia during testosterone replacement therapy. 6
• The European Academy of Andrology does not recommend routine use of aromatase inhibitors for general gynecomastia management. 5

Androgens for Hypogonadal Men

Testosterone replacement should only be offered to men with proven testosterone deficiency and documented low testosterone levels. 5, 7

• Testosterone therapy is not indicated for eugonadal men with gynecomastia. 5
• In hypogonadal men, correcting testosterone deficiency may help resolve gynecomastia. 8

Treatment Based on Underlying Etiology

Spironolactone-Induced Gynecomastia

For men on spironolactone (for primary aldosteronism or other conditions), switch to eplerenone to avoid anti-androgenic side effects. 9

• Spironolactone causes gynecomastia in 10% of men at 25 mg/day and up to 52% at doses ≥150 mg/day. 9
• Eplerenone lacks anti-androgenic effects and is the preferred mineralocorticoid receptor antagonist in men. 9
• If dose reduction of spironolactone to ≤50 mg/day doesn't resolve gynecomastia, switching to eplerenone or amiloride is recommended. 10

Androgen Deprivation Therapy-Related Gynecomastia

For men on androgen deprivation therapy who develop gynecomastia after treatment initiation, no effective pharmacological reversal exists; prevention with prophylactic breast irradiation is key. 3, 11, 4

• Gynecomastia incidence varies with ADT method, reaching up to 80% with estrogen therapy. 11
• Non-hormonal pharmacologic treatments (antidepressants, anticonvulsants) may help manage associated vasomotor symptoms but not the breast tissue itself. 11

When Pharmacological Treatment is NOT Recommended

The European Academy of Andrology recommends against routine use of SERMs, aromatase inhibitors, or non-aromatizable androgens for general gynecomastia management. 5

• Watchful waiting is recommended after treating underlying pathology or discontinuing causative medications. 5
• Pubertal gynecomastia: Resolves spontaneously in >90% of cases within 24 months; pharmacological treatment is not routinely indicated. 5
• Long-standing gynecomastia: Pharmacological therapy is ineffective once significant fibrosis has developed; surgical treatment becomes the therapy of choice. 5, 8

Critical Diagnostic Workup Before Treatment

Before initiating any pharmacological therapy, the following must be evaluated: 5, 7

• Laboratory tests: Total testosterone, estradiol, SHBG, LH, FSH, hCG, prolactin, TSH, liver and renal function. 5, 7
• Testicular ultrasound: To rule out testicular tumors (palpation has low sensitivity). 5, 7
• Medication review: Identify and discontinue drugs associated with gynecomastia when possible. 5
• Breast examination: Confirm glandular tissue versus lipomastia; rule out breast cancer. 5

Common Pitfalls to Avoid

• Do not use tamoxifen in estrogen-sensitive conditions without proper evaluation, as it has mixed agonist/antagonist effects. 12
• Do not prescribe testosterone to eugonadal men with gynecomastia, as it may worsen the condition through aromatization to estradiol. 5
• Do not delay investigation in adult-onset gynecomastia; underlying pathology is found in 45-50% of cases. 5, 13
• Do not assume all breast enlargement is benign; male breast cancer must be excluded, particularly in unilateral cases. 5, 7